At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QURE uniQure NV
Post-Mkt 04-15 16:33:23 EDT
17.25
+0.16
+0.94%
盘后17.25
+0.000.00%
16:23 EDT
High17.55Low16.76Vol1.45M
Open17.30D1 Closing17.09Amplitude4.59%
Mkt Cap1.07BTradable Cap700.98MTotal Shares62.29M
T/O24.88MT/O Rate3.57%Tradable Shares40.64M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

uniQure put volume heavy and directionally bearish
TIPRANKS  ·  04-11
uniQure put volume heavy and directionally bearish
uniQure put volume heavy and directionally bearish
TIPRANKS  ·  04-08
uniQure put volume heavy and directionally bearish
uniQure (QURE) Faces FDA Rebuke, Lawsuits Over AMT-130 Disclosures Is Its Credibility at Risk?
Simply Wall St.  ·  04-06
uniQure (QURE) Faces FDA Rebuke, Lawsuits Over AMT-130 Disclosures Is Its Credibility at Risk?
uniQure Is Maintained at Equal-Weight by Barclays
Dow Jones  ·  03-23
uniQure Is Maintained at Equal-Weight by Barclays
Uniqure Nv : Barclays Cuts Target Price to $25 From $31
THOMSON REUTERS  ·  03-23
Uniqure Nv : Barclays Cuts Target Price to $25 From $31
uniQure (QURE) Receives a Hold from Barclays
TIPRANKS  ·  03-23
uniQure (QURE) Receives a Hold from Barclays
uniQure faces securities class action over AMT-130 FDA disclosures
Reuters  ·  03-19
uniQure faces securities class action over AMT-130 FDA disclosures
UniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh
Simply Wall St.  ·  03-12
UniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh
Uniqure Nv : Mizuho Raises to Outperform From Neutral; Raises Target Price to $35 From $12
THOMSON REUTERS  ·  03-11
Uniqure Nv : Mizuho Raises to Outperform From Neutral; Raises Target Price to $35 From $12
uniQure Price Target Maintained With a $70.00/Share by HC Wainwright & Co.
Dow Jones  ·  03-10
uniQure Price Target Maintained With a $70.00/Share by HC Wainwright & Co.
Chardan Raises Price Target on uniQure to $31 From $16, Keeps Buy Rating
MT Newswires Live  ·  03-10
Chardan Raises Price Target on uniQure to $31 From $16, Keeps Buy Rating
uniQure Is Maintained at Buy by Chardan Capital
Dow Jones  ·  03-10
uniQure Is Maintained at Buy by Chardan Capital
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
Benzinga  ·  03-10
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
uniQure price target raised to $31 from $16 at Chardan
TIPRANKS  ·  03-10
uniQure price target raised to $31 from $16 at Chardan
U.S. Chess Champion Sitting on Huge 42.33% uniQure (QURE) Loss
TIPRANKS  ·  03-10
U.S. Chess Champion Sitting on Huge 42.33% uniQure (QURE) Loss
This biotech's stock is soaring after a 'polarizing' FDA official is stepping down
Dow Jones  ·  03-09
This biotech's stock is soaring after a 'polarizing' FDA official is stepping down
Top Premarket Gainers
MT Newswires Live  ·  03-09
Top Premarket Gainers
Why Is uniQure Stock Skyrocketing Monday?
Benzinga_recent_news  ·  03-09
Why Is uniQure Stock Skyrocketing Monday?
Uniqure Nv : Wells Fargo Raises to Overweight From Equal Weight; Raises Target Price to $60 From $15
THOMSON REUTERS  ·  03-09
Uniqure Nv : Wells Fargo Raises to Overweight From Equal Weight; Raises Target Price to $60 From $15
uniQure upgraded to Overweight from Equal Weight at Wells Fargo
TIPRANKS  ·  03-09
uniQure upgraded to Overweight from Equal Weight at Wells Fargo

Introduction

Company Name.
uniQure NV
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Issue price:
--